Register or Login
All
  • All
  • Uniprot Id
  • Catalog #
  • Peptide Sequence
COVID19
>   home   >   Products   >   Primary Antibodies   >   Immunology   >   Anti-CD55 (Extracellular region) Antibody   

Anti-CD55 (Extracellular region) Antibody

     
  •  - Anti-CD55 (Extracellular region) Antibody AN1697
    Immunocytochemical labeling of CD55 in paraformaldehyde fixed human MDA-MB-231 breast cancer cells. The cells were labeled with mouse monoclonal anti-CD55 (CM0331). The antibody was detected using goat anti-mouse DyLight® 594.
    detail
  •  - Anti-CD55 (Extracellular region) Antibody AN1697
    Representative Standard Curve using mouse monoclonal anti-CD55 (CM0331) for ELISA capture of human recombinant CD55 extracellular region with His-tag. Capture was detected by using an anti-His-tag antibody followed by appropriate secondary antibody conjugated to HRP.
    detail
  • SPECIFICATION
  • CITATIONS
  • PROTOCOLS
  • BACKGROUND
  • detail
Product Information
Application
  • Applications Legend:
  • WB=Western Blot
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin-embedded Sections)
  • IHC-F=Immunohistochemistry (Frozen Sections)
  • IF=Immunofluorescence
  • FC=Flow Cytopmetry
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • E=ELISA
  • IP=Immunoprecipitation
  • DB=Dot Blot
  • CHIP=Chromatin Immunoprecipitation
  • FA=Fluorescence Assay
  • IEM=Immuno electron microscopy
  • EIA=Enzyme Immunoassay
WB, IHC
Primary Accession P08174
Host Mouse
Clonality Mouse Monoclonal
Isotype IgG1
Clone Names M033
Calculated MW 41400 Da
Additional Information
Gene ID 1604
Other Names Complement decay-accelerating factor, DAF, CD_antigen, CD55, CR
Target/Specificity CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.
Format Protein G Purified
StorageMaintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
PrecautionsAnti-CD55 (Extracellular region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
ShippingBlue Ice
Research Areas
Citations (0)
citation

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.

Submit your citation using an Abcepta antibody to
info@abcepta.com, and receive a free "I Love Antibodies" mug.

Background

CD55, also known as Decay-accelerating factor (DAF) is an inhibitor of the complement system, and is broadly expressed in malignant tumours. In cancer, CD55 has been implicated in tumorigenesis, neoangiogenesis, and metastasis. CD55 may decrease complement mediated tumor cell lysis, inhibit tumor apoptosis, and promote invasive cancer cell motility. These roles in cancer may involve binding to the seven-span transmembrane receptor CD97. In neuroblastoma cells, CD55 contributes to growth of colonies and to invasion of cells, but not to stemness. In neuroblastoma cells, CD55 is upregulated in a small population of cells that are HIF-2α positive. This CD55 positive subpopulation is highly invasive and has low adhesion to fibronectin and collagen. In addition, CD55 expression correlates with poor prognosis in neuroblastoma patients.

FeedBack
Abcepta welcomes feedback from its customers.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abcepta.com.

$ 360.00
Cat# AN1697
Size:
Quantity:
Availability: 7-10 days
Bulk Size

Ordering Information

United States
AlbaniaAustraliaAustriaBelgiumBosnia & HerzegovinaBrazilBulgariaCanadaCentral AmericaChinaCroatiaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHong KongHungaryIcelandIndiaIndonesiaIrelandIsraelItalyJapanLatviaLithuaniaLuxembourgMacedoniaMalaysiaMaltaNetherlandsNew ZealandNorwayPakistanPolandPortugalRomaniaSerbiaSingaporeSlovakiaSloveniaSouth AfricaSouth KoreaSpainSwedenSwitzerlandTaiwanTurkeyUnited KingdomUnited StatesVietnamWorldwideOthers
Abcepta, Inc.
(888) 735-7227 / (858) 622-0099
(858) 622-0609
USA Headquarters
(888) 735-7227 / (858) 622-0099 or (858) 875-1900

Shipping Information

Domestic orders (in stock items)
Shipped out the same day. Orders placed after 1 PM (PST) will ship out the next business day.
International orders
Contact your local distributors
Terms & Conditions
"